Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist
呼吸道合胞病毒(RSV)是一种季节性病毒,每年感染6400万儿童和成人的肺和气道。它是急性下呼吸道感染的主要原因,并且与明显的发病率和死亡率有关。尽管医疗和经济负担沉重,但与RSV相关的细支气管炎和肺炎的治疗选择仍然有限,主要包括支持治疗。该出版物涵盖了导致鉴定JNJ-53718678的药物
化学工作,JNJ-53718678是口服可
生物利用的RSV
抑制剂,在健康成人受试者的2a期挑战研究中显示出有效,目前正在住院婴儿和成人中进行评估。